The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

LAZEBEMIDE     N-(2-aminoethyl)-5-chloro- pyridine-2...

Synonyms: Lazabemide, CHEMBL279390, SureCN121998, CCRIS 7301, CHEBI:121860, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CCRIS 7301

  • Lazabemide therapy did not induce clinically significant arrhythmias [1].
  • Fifty-one patients with PD who did not have clinically apparent heart disease were randomized in a double-blind fashion to receive either lazabemide (n = 25) or placebo (n = 26) treatments [1].
  • Therefore, it is natural to expect that monoamine oxidase inhibitors, deprenyl or lazabemide, could exhibit beneficial effects on parkinsonism, i.e. symptomatic effects [2].

Psychiatry related information on CCRIS 7301


High impact information on CCRIS 7301


Biological context of CCRIS 7301


Anatomical context of CCRIS 7301


Associations of CCRIS 7301 with other chemical compounds


Gene context of CCRIS 7301


Analytical, diagnostic and therapeutic context of CCRIS 7301

  • To evaluate whether lazabemide has proarrhythmic or hypotensive potency in Parkinson's disease (PD), we conducted an 8-week, double-blind, placcbo-controlled, parallel group study with use of 24-hour ambulatory electrocardiographic (ECG) monitoring [1].


  1. Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease. Narabayashi, H., Yamaguchi, T., Sugi, K., Mitamura, H., Mizuno, Y., Nakashima, M. Clinical neuropharmacology. (1999) [Pubmed]
  2. Short review on monoamine oxidase and its inhibitors. Kanazawa, I. Eur. Neurol. (1994) [Pubmed]
  3. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Berlin, I., Aubin, H.J., Pedarriosse, A.M., Rames, A., Lancrenon, S., Lagrue, G. Addiction (2002) [Pubmed]
  4. Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives. Cesura, A.M., Borroni, E., Gottowik, J., Kuhn, C., Malherbe, P., Martin, J., Richards, J.G. Advances in neurology. (1999) [Pubmed]
  5. Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives. Lebreton, L., Curet, O., Gueddari, S., Mazouz, F., Bernard, S., Burstein, C., Milcent, R. J. Med. Chem. (1995) [Pubmed]
  6. Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. Mason, R.P., Olmstead, E.G., Jacob, R.F. Biochem. Pharmacol. (2000) [Pubmed]
  7. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Bondiolotti, G.P., Galva, M.D., Villa, F., Sciaba, L., Picotti, G.B. Biochem. Pharmacol. (1995) [Pubmed]
  8. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects. Dingemanse, J., Wood, N., Jorga, K., Kettler, R. British journal of clinical pharmacology. (1997) [Pubmed]
  9. Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis. Cesura, A.M., Gottowik, J., Lahm, H.W., Lang, G., Imhof, R., Malherbe, P., Röthlisberger, U., Da Prada, M. Eur. J. Biochem. (1996) [Pubmed]
  10. The activity of MAO A and B in rat renal cells and tubules. Guimarães, J.T., Soares-da-Silva, P. Life Sci. (1998) [Pubmed]
  11. The density of monoamine oxidase B sites is not altered in the postmortem brain of alcoholics. Maeztu, A.I., Ballesteros, J., Callado, L.F., Gutiérrez, M., Meana, J.J. Alcohol. Clin. Exp. Res. (1997) [Pubmed]
  12. Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway. Macinnes, N., Duty, S. Br. J. Pharmacol. (2004) [Pubmed]
  13. Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex. Guimarães, J.T., Vindis, C., Soares-da-Silva, P., Parini, A. Life Sci. (2003) [Pubmed]
  14. Determination of Ro 19-6327 (Lazabemide) in human plasma and urine by gas chromatography-negative chemical ionization mass spectrometry. Davis, P.P., Crews, T., Bradford, J.J., Edom, R.W. J. Chromatogr. B, Biomed. Appl. (1995) [Pubmed]
  15. Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy. Mousseau, D.D., Baker, G.B., Butterworth, R.F. J. Neurochem. (1997) [Pubmed]
  16. Inhibition of monoamine oxidase modulates the behaviour of semicarbazide-sensitive amine oxidase (SSAO). Fitzgerald, D.H., Tipton, K.F. Journal of neural transmission (Vienna, Austria : 1996) (2002) [Pubmed]
WikiGenes - Universities